Gastrointestinal peptides and bone health
暂无分享,去创建一个
Herbert Herzog | P. Baldock | H. Herzog | I. P. Wong | Paul A Baldock | Iris Pl Wong | Iris P. L. Wong
[1] Wei Liu,et al. Connective tissue growth factor is a downstream mediator for preptin-induced proliferation and differentiation in human osteoblasts , 2010, Amino Acids.
[2] P. Esbrit,et al. Exendin-4 exerts osteogenic actions in insulin-resistant and type 2 diabetic states , 2010, Regulatory Peptides.
[3] J. Holst,et al. Four-month treatment with GLP-2 significantly increases hip BMD: a randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD. , 2009, Bone.
[4] J. Holst,et al. Short Bowel Patients Treated for Two Years with Glucagon-Like Peptide 2: Effects on Intestinal Morphology and Absorption, Renal Function, Bone and Body Composition, and Muscle Function , 2009, Gastroenterology research and practice.
[5] E. Poggiogalle,et al. Relationships of acylated and des-acyl ghrelin levels to bone mineralization in obese children and adolescents. , 2009, Bone.
[6] N. Gunes,et al. Effects of amylin on bone development and egg production in hens. , 2009, Poultry science.
[7] J. Alonso,et al. Devazepide, a nonpeptide antagonist of CCK receptors, induces apoptosis and inhibits Ewing tumor growth , 2009, Anti-cancer drugs.
[8] A. Klibanski,et al. Peptide YY in adolescent athletes with amenorrhea, eumenorrheic athletes and non-athletic controls. , 2009, Bone.
[9] P. Esbrit,et al. Effect of GLP-1 Treatment on Bone Turnover in Normal, Type 2 Diabetic, and Insulin-Resistant States , 2009, Calcified Tissue International.
[10] W. Zhong,et al. Ghrelin stimulates proliferation of human osteoblastic TE85 cells via NO/cGMP signaling pathway , 2009, Endocrine.
[11] J. John Mann,et al. Lrp5 Controls Bone Formation by Inhibiting Serotonin Synthesis in the Duodenum , 2008, Cell.
[12] T. Nagao,et al. Pancreatic polypeptide is secreted from and controls differentiation through its specific receptors in osteoblastic MC3T3-E1 cells , 2008, Peptides.
[13] A. Klibanski,et al. Peptide YY (PYY) levels and bone mineral density (BMD) in women with anorexia nervosa. , 2008, Bone.
[14] M. Goldstein,et al. Prognostic indicators of changes in bone density measures in adolescent girls with anorexia nervosa-II. , 2008, The Journal of clinical endocrinology and metabolism.
[15] B. Uzan,et al. Adrenomedullin is anti‐apoptotic in osteoblasts through CGRP1 receptors and MEK‐ERK pathway , 2008, Journal of cellular physiology.
[16] R. Wildman,et al. Change in adipocytokines and ghrelin with menopause. , 2008, Maturitas.
[17] D. Drucker,et al. The murine glucagon-like peptide-1 receptor is essential for control of bone resorption. , 2008, Endocrinology.
[18] J. Holst,et al. Effects of treatment with glucagon-like peptide-2 on bone resorption in colectomized patients with distal ileostomy or jejunostomy and short-bowel syndrome , 2008, Scandinavian journal of gastroenterology.
[19] W. Bollag,et al. Impact of Glucose‐Dependent Insulinotropic Peptide on Age‐Induced Bone Loss , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[20] J. Herman,et al. Peptide YY regulates bone turnover in rodents. , 2007, Gastroenterology.
[21] K. Yaffe,et al. Use of antidepressants and rates of hip bone loss in older women: the study of osteoporotic fractures. , 2007, Archives of internal medicine.
[22] W. Bollag,et al. Glucose-dependent insulinotropic peptide-overexpressing transgenic mice have increased bone mass. , 2007, Bone.
[23] J. Alonso,et al. Cholecystokinin Down-Regulation by RNA Interference Impairs Ewing Tumor Growth , 2007, Clinical Cancer Research.
[24] J. Holst,et al. Disassociation of bone resorption and formation by GLP-2: a 14-day study in healthy postmenopausal women. , 2007, Bone.
[25] W. Bollag,et al. Effects of glucose-dependent insulinotropic peptide on osteoclast function. , 2007, American journal of physiology. Endocrinology and metabolism.
[26] J. Richards,et al. Effect of selective serotonin reuptake inhibitors on the risk of fracture. , 2007, Archives of internal medicine.
[27] J. Holst,et al. Bone resorption is decreased postprandially by intestinal factors and glucagon-like peptide-2 is a possible candidate , 2007, Scandinavian journal of gastroenterology.
[28] Yuichiro Yamada,et al. Gastric inhibitory polypeptide as an endogenous factor promoting new bone formation after food ingestion. , 2006, Molecular endocrinology.
[29] H. Morris,et al. Effects of Amylin Deficiency on Trabecular Bone in Young Mice Are Sex-Dependent , 2006, Calcified Tissue International.
[30] A. Klibanski,et al. Elevated peptide YY levels in adolescent girls with anorexia nervosa. , 2006, The Journal of clinical endocrinology and metabolism.
[31] W. Bollag,et al. Glucose-dependent insulinotropic polypeptide receptor knockout mice have altered bone turnover. , 2005, Bone.
[32] K. Park,et al. Ghrelin stimulates proliferation and differentiation and inhibits apoptosis in osteoblastic MC3T3-E1 cells. , 2005, Bone.
[33] Bart O. Williams,et al. Essential Role of β-Catenin in Postnatal Bone Acquisition* , 2005, Journal of Biological Chemistry.
[34] Hans Clevers,et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. , 2005, Developmental cell.
[35] S. Bloom,et al. Ghrelin, peptide YY, glucose-dependent insulinotropic polypeptide, and hunger responses to a mixed meal in anorexic, obese, and control female adolescents. , 2005, The Journal of clinical endocrinology and metabolism.
[36] A. Robling,et al. Inhibition of the serotonin (5-hydroxytryptamine) transporter reduces bone accrual during growth. , 2005, Endocrinology.
[37] S. Takeda,et al. Ghrelin Directly Regulates Bone Formation , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[38] I. Reid,et al. Shared pathways of osteoblast mitogenesis induced by amylin, adrenomedullin, and IGF-1. , 2004, Biochemical and biophysical research communications.
[39] Hui Zheng,et al. Ghrelin stimulation of growth hormone release and appetite is mediated through the growth hormone secretagogue receptor. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[40] R. Průša,et al. Amylin fasting plasma levels are decreased in patients with osteoporosis , 2004, Osteoporosis International.
[41] C. Laplace,et al. Amylin inhibits bone resorption while the calcitonin receptor controls bone formation in vivo , 2004, The Journal of cell biology.
[42] A. Schwartz,et al. Diabetes Mellitus: Does it Affect Bone? , 2003, Calcified Tissue International.
[43] J. Holst,et al. Role of Gastrointestinal Hormones in Postprandial Reduction of Bone Resorption , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[44] Yuxiang Sun,et al. Deletion of Ghrelin Impairs neither Growth nor Appetite , 2003, Molecular and Cellular Biology.
[45] Mohammad A Ghatei,et al. Inhibition of food intake in obese subjects by peptide YY3-36. , 2003, The New England journal of medicine.
[46] C. Schwarzer,et al. Synergistic Effects of Y2 and Y4 Receptors on Adiposity and Bone Mass Revealed in Double Knockout Mice , 2003, Molecular and Cellular Biology.
[47] H. Grill,et al. Meal-related ghrelin suppression requires postgastric feedback. , 2003, Endocrinology.
[48] K. Kitamura,et al. Adrenomedullin stimulates the growth of cultured normal human osteoblasts as an autocrine/paracine regulator , 2002, Peptides.
[49] I. Reid. Relationships among body mass, its components, and bone. , 2002, Bone.
[50] S. Khosla,et al. Use of site-specific antibodies to characterize the circulating form of big insulin-like growth factor II in patients with hepatitis C-associated osteosclerosis. , 2002, The Journal of clinical endocrinology and metabolism.
[51] I. Reid. Relationships among body mass, its components, and bone 1 1 Published simultaneously at BoneKEy-Oste , 2002 .
[52] Richard P Lifton,et al. High bone density due to a mutation in LDL-receptor-related protein 5. , 2002, The New England journal of medicine.
[53] C. Hartmann,et al. Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor , 2002, The Journal of cell biology.
[54] G. Thomas,et al. Hypothalamic Y2 receptors regulate bone formation. , 2002, The Journal of clinical investigation.
[55] C. Buchanan,et al. Preptin derived from proinsulin-like growth factor II (proIGF-II) is secreted from pancreatic islet beta-cells and enhances insulin secretion. , 2001, The Biochemical journal.
[56] Miikka Vikkula,et al. LDL Receptor-Related Protein 5 (LRP5) Affects Bone Accrual and Eye Development , 2001, Cell.
[57] K. Hosoda,et al. Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans. , 2001, The Journal of clinical endocrinology and metabolism.
[58] B. Wisse,et al. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. , 2001, Diabetes.
[59] I. Reid,et al. Effects of calcitonin, amylin, and calcitonin gene-related peptide on osteoclast development. , 2001, Bone.
[60] R. Bollag,et al. Glucose-dependent insulinotropic peptide is an integrative hormone with osteotropic effects , 2001, Molecular and Cellular Endocrinology.
[61] I. Reid,et al. A potential role for adrenomedullin as a local regulator of bone growth. , 2001, Endocrinology.
[62] A. Young,et al. Amylin and Bone Metabolism in Streptozotocin‐Induced Diabetic Rats , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[63] O. Smithies,et al. Extreme hydrops fetalis and cardiovascular abnormalities in mice lacking a functional Adrenomedullin gene. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[64] V. Coxam,et al. Amylin inhibits ovariectomy-induced bone loss in rats. , 2000, The Journal of endocrinology.
[65] H. Rasmussen,et al. Osteoblast-derived cells express functional glucose-dependent insulinotropic peptide receptors. , 2000, Endocrinology.
[66] M. Nakazato,et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach , 1999, Nature.
[67] P. Nawroth,et al. The Effect of Pramlintide (Amylin Analogue) Treatment on Bone Metabolism and Bone Density in Patients with Type 1 Diabetes Mellitus , 1999, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
[68] S. Kahn,et al. Human aging is associated with parallel reductions in insulin and amylin release. , 1998, American journal of physiology. Endocrinology and metabolism.
[69] I. Reid,et al. Systemic administration of amylin increases bone mass, linear growth, and adiposity in adult male mice. , 1998, American journal of physiology. Endocrinology and metabolism.
[70] Teresa To,et al. Use of selective serotonin-reuptake inhibitors or tricyclic antidepressants and risk of hip fractures in elderly people , 1998, The Lancet.
[71] C. Ohlsson,et al. Growth hormone and bone. , 1998, Endocrine reviews.
[72] I. Reid,et al. Adrenomedullin is a potent stimulator of osteoblastic activity in vitro and in vivo. , 1997, American journal of physiology. Endocrinology and metabolism.
[73] A. Jullienne,et al. Expression of glucagon‐like peptide 1 receptor in a murine C cell line Regulation of calcitonin gene by glucagon‐like peptide 1 , 1996, FEBS letters.
[74] A. Crespel,et al. Effects of glucagon and glucagon-like peptide-1 (7-36) amide (tGLP-1) on C-cells from rat thyroid and medullary thyroid carcinoma CA-77 cell line , 1996, Regulatory Peptides.
[75] T. Moody,et al. Regulation of insulin secretion and blood glucose metabolism by adrenomedullin. , 1996, Endocrinology.
[76] I. Reid,et al. Amylin stimulates osteoblast proliferation and increases mineralized bone volume in adult mice. , 1995, Biochemical and biophysical research communications.
[77] R. Hazelwood. The Pancreatic Polypeptide (PP-Fold) Family: Gastrointestinal, Vascular, and Feeding Behavioral Implications , 1993, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[78] V. Tillmann,et al. Effect of pubertal development and physical activity on plasma ghrelin concentration in boys , 2009, Journal of endocrinological investigation.
[79] I. Reid,et al. Preptin, another peptide product of the pancreatic beta-cell, is osteogenic in vitro and in vivo. , 2007, American journal of physiology. Endocrinology and metabolism.
[80] H. Pols,et al. Ghrelin and unacylated ghrelin stimulate human osteoblast growth via mitogen-activated protein kinase (MAPK)/phosphoinositide 3-kinase (PI3K) pathways in the absence of GHS-R1a. , 2006, The Journal of endocrinology.
[81] D. Cocchi,et al. Ghrelin regulates proliferation and differentiation of osteoblastic cells. , 2005, The Journal of endocrinology.
[82] J. Hughes,et al. Cholecystokinin receptors , 2005, Cellular and Molecular Neurobiology.
[83] M. Bouxsein,et al. Essential role of beta-catenin in postnatal bone acquisition. , 2005, The Journal of biological chemistry.
[84] J. Holst,et al. Reduction of nocturnal rise in bone resorption by subcutaneous GLP-2. , 2004, Bone.
[85] C. Schwarzer,et al. Synergistic Effects of Y 2 and Y 4 Receptors on Adiposity and Bone Mass Revealed in Double Knockout Mice , 2003 .
[86] M. Nakazato,et al. Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. , 2002, The Journal of clinical endocrinology and metabolism.
[87] Mark L. Johnson,et al. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. , 2002, American journal of human genetics.
[88] A.,et al. Effects of Glucagon and Glucagon-Like Peptide-l-(736) Amide on C Cells from Rat Thyroid and Medullary Thyroid Carcinoma CA-77 Cell Line , 2001 .